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Nuclear corepressor 1 (NCoR) associates with nuclear receptors and
other transcription factors leading to transcriptional repression.
We show here that NCoR depletion enhances cancer cell invasion
and increases tumor growth and metastatic potential in nude
mice. These changes are related to repressed transcription of genes
associated with increased metastasis and poor prognosis in patients.
Strikingly, transient NCoR silencing leads to heterochromatinization
and stable silencing of the NCoR gene, suggesting that NCoR loss can
be propagated, contributing to tumor progression even in the ab-
sence of NCoR gene mutations. Down-regulation of the thyroid hor-
mone receptor β1 (TRβ) appears to be associated with cancer onset
and progression. We found that expression of TRβ increases NCoR
levels and that this induction is essential in mediating inhibition of
tumor growth and metastasis by this receptor. Moreover, NCoR is
down-regulated in human hepatocarcinomas and in the more ag-
gressive breast cancer tumors, and its expression correlates positively
with that of TRβ. These data provide a molecular basis for the anti-
cancer actions of this corepressor and identify NCoR as a potential
molecular target for development of novel cancer therapies.
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Corepressors play a central role in bridging chromatin-modi-fying enzymes and transcription factors (1). NCoR (nuclear
corepressor 1) and the homologous protein SMRT (silencing
mediator or retinoic and thyroid hormone receptors or NCoR2)
were identified by their interaction with unliganded thyroid
hormone receptors (TRs) and retinoic acid receptors (2, 3), al-
though later studies demonstrated that they also could bind to
other transcription factors (4). NCoR and SMRT belong to large
complexes that contain histone deacetylases (HDACs), thereby
inducing chromatin compaction and gene silencing (4–7). Although
these corepressors interact with multiple HDACs, HDAC3 plays a
key role in mediating their actions (8, 9) and is essential for re-
pression by TRs (10, 11).
As expected from their prevalent role in integrating the action
of many transcription factors, NCoR and HDAC3 affect numer-
ous developmental and homeostatic processes (12). In addition,
there is increasing evidence that NCoR could play a significant
role in cancer. Alterations in NCoR expression or subcellular lo-
calization have been linked to various solid tumors. Thus, reduced
NCoR expression has been associated with invasive breast tumors
(13, 14), shorter relapse-free survival (15), and resistance to an-
tiestrogen treatment (16). Unbiased pathway analysis recently
has revealed mutations of NCoR (17, 18) among the driver mu-
tations in breast tumors (19). The human NCoR gene is lo-
cated on a region of chromosome 17p frequently deleted in
hepatocarcinoma (HCC) (20, 21), suggesting that loss of this co-
repressor could drive liver cancer also. In agreement with this idea,
liver-specific deletion of HDAC3 caused spontaneous develop-
ment of HCC in mice, showing its essential role in the maintenance
of chromatin structure and genome stability (22). Furthermore, the
expression of HDAC3 and NCoR was down-regulated in a subset
of human HCCs (22). All these findings suggest that NCoR could
be an important suppressor of cancer initiation or progression,
but the mechanisms by which the corepressor exerts its tumor-
suppressing role have not yet been examined.
TRs, and in particular TRβ1, can act as tumor suppressors (23).
We have shown that this receptor retards tumor growth and sup-
presses invasion, extravasation, and metastasis formation in nude
mice (23–26). These tumor-suppressing effects are associated with a
decreased expression of prometastatic genes (23). The role of TRβ1
appears to be particularly relevant in liver cancer. Thus, thyroid
Significance
Inactivating nuclear corepressor 1 (NCoR) mutations have been
found in human tumors. Here, we report that NCoR has a tumor-
suppressive role, inhibiting extravasation, metastasis formation,
and tumor growth in mice. These changes are related to re-
pressed transcription of genes associated with increased metas-
tasis and poor prognosis in cancer patients. An autoregulatory
loop maintains NCoR gene expression, suggesting that NCoR loss
can be propagated, contributing to tumor progression in the
absence of NCoR gene mutations. The nuclear receptor thyroid
hormone receptor β1 increases NCoR expression, and this in-
duction is essential in mediating its tumor-suppressive actions.
Both are reduced in human hepatocarcinoma and aggressive
breast cancer tumors, identifying NCoR as a potential molecular
target for the development of novel therapies.
Author contributions: O.A.M.-I. and A.A. designed research; O.A.M.-I., E.A.-M., S.G.-R., J.P.V.-M.,
R.M.O., E.L., R.G.M., I.I.d.C., A.F.F., and P.G.-P. performed research; C.V. and J.P. contributed
new reagents/analytic tools; O.A.M.-I., E.A.-M., J.P.V.-M., R.M.O., I.I.d.C., A.F.F., M.F.F., J.R.,
and A.A. analyzed data; and A.A. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
1To whom correspondence should be addressed. Email: aaranda@iib.uam.es.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1520469113/-/DCSupplemental.
E328–E337 | PNAS | Published online January 4, 2016 www.pnas.org/cgi/doi/10.1073/pnas.1520469113
hormones binding to TRβ1 induce regression of carcinogen-induced
nodules, reducing the incidence of HCC and lung metastasis in
rodents (27, 28), and TRβ1 down-regulation appears to be associ-
ated with HCC onset and progression (29). In addition, aberrant
TRs that act as dominant-negative inhibitors of wild-type TR ac-
tivity and that have altered association with corepressors have been
found frequently in human HCCs (30, 31).
Here, we show that NCoR depletion enhances cellular invasion
in vitro and increases tumor growth and the metastatic potential in
nude mice. These actions are related to the regulation of genes
associated with metastatic growth and poor outcome in cancer
patients. Furthermore, we demonstrate the existence of a positive
autoregulatory loop that maintains NCoR gene expression. NCoR
depletion results in heterochromatinization and long-term silencing
of NCoR transcription. Silencing could represent an important
oncogenic mechanism in tumors in which inactivating mutations in
the NCoR gene are not present. Finally, we show that induction of
NCoR is an essential mediator of the tumor-suppressing actions of
TRβ1 and that both are down-regulated in human HCC and in
estrogen receptor-negative (ER−) breast tumors, demonstrating a
positive correlation between the expression of the receptor and the
corepressor. Taken together, our results define NCoR as a potent
tumor suppressor and as a potential target for cancer therapy.
Results
NCoR Represses Expression of Prometastatic Genes. mRNAs of se-
lected prometastatic genes, including cyclooxigenase 2 (COX2),
DNA-binding protein inhibitor 1 (ID1), C-MET, matrix metal-
lopeptidase (MMP)2, MMP9, CXCR4, CCR1, CCR6, and CCR7,
were measured in SK-hep1 (SK) cells transfected with a control
siRNA or with an NCoR-specific siRNA. These cells were derived
from a patient with liver adenocarcinoma and recently have been
shown to have an oncogenic mesenchymal stem cell phenotype
(32). Most of these genes were significantly increased upon
NCoR depletion in SK cells (Fig. 1A) and in MDA-MB-468
(MDA) breast cancer cells (Fig. 1B). Because TRβ expression
significantly increased NCoR mRNA and protein levels in SK
and MDA cells (Fig. S1A), and prometastatic genes are re-
pressed by TRβ, we reasoned that increased NCoR levels could
play a role in this repression. Thus, we also measured prometastatic
gene expression in SK-TRβ and MDA-TRβ cells, finding that
the repressive effect of TRβ was reversed to a significant extent,
or even totally in some cases, in NCoR-depleted cells (Fig. 1).
Surprisingly, most of the effect of TRβ appears to be ligand
independent, because incubation with triiodothyronine (T3)
had little effect on transcript levels of NCoR and prometastatic
genes (Fig. S1B). Similar changes were observed in human
HepG2 HCC cells and in nontumoral HH4 human hepatocytes
(Fig. S2 A and B), showing that TRβ also has a role as a direct
regulator of NCoR in hepatocytes and the importance of the
corepressor as an inhibitor of prometastatic gene expression.
NCoR overexpression in SK and SK-TRβ cells reversed the
effect of the siNCoR in prometastatic gene expression, elimi-
nating the off-target effects of the siRNA pool used (Fig. S1C).
Fig. 1. NCoR depletion increases the expression of
prometastatic genes. (A) mRNA levels of prometa-
static genes in SK and SK-TRβ cells transfected with
siControl or siNCoR. Data (means ± SD) are expressed
relative to the values obtained in SK cells transfected
with siControl. A Western blot of NCoR protein lev-
els is shown. (B) An experiment in MDA and MDA-
TRβ cells similar to that shown in A.
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In contrast with the crucial role of NCoR, efficient knockdown
of the SMRT corepressor did not increase the expression of
these genes, indicating that it does not participate in their
regulation (Fig. S2 C and D).
We next conducted transient transfection studies with lucif-
erase promoter constructs of prometastatic genes in SK cells.
Proximal promoter sequences of the COX2, ID1, and MMP9
genes containing binding sites for various transcription factors
appear to mediate both basal promoter activity and TRβ in-
hibition (Fig. 2A). Furthermore, in SK-TRβ cells the receptor
was constitutively bound to these sequences in ChIP assays, and
NCoR and HDAC3 recruitment to the promoters was enhanced
significantly in comparison with the parental cells. In parallel
with this increase, histone H3 acetylation was reduced and the
repressive histone marker H3K9me3 was increased in SK-TRβ
cells (Fig. 2B). In the ID1 gene additional control regions have
been identified (33), and although an irrelevant upstream region
and the −1006/−746 control region were unaffected, the −1817/
−1609 fragment also bound NCoR and TRβ, and the epigenetic
changes observed were similar to those found with the more
proximal promoter sequences (Fig. 2B). To analyze the func-
tional role of NCoR in promoter regulation, the impact of NCoR
gain of function and loss of function was evaluated in trans-
fection assays. Overexpression of NCoR reduced promoter ac-
tivity in SK cells to levels similar to those found in SK-TRβ cells.
Conversely, NCoR depletion normalized promoter activity in the
cells expressing the receptor (Fig. 2C), demonstrating the es-
sential role of this corepressor in the inhibitory effect of TRβ on
Fig. 2. NCoR represses promoter activity of prom-
etastatic genes. (A) Transient transfection assays in
SK and SK-TRβ cells with luciferase reporters of the
COX2, MMP9, and ID1 promoters or an empty plas-
mid (e.p). Schematics of the plasmids used showing
the putative binding motifs for different transcrip-
tion factors are illustrated. Cells were treated with
and without 5 nM T3 for 36 h as indicated. Data are
means ± SD and are expressed relative to the lucif-
erase activity obtained in untreated SK cells. (B) ChIP
assays in SK and SK-TRβ cells with the antibodies and
the promoter regions indicated. (C) Luciferase assays
(mean ± SD) with the indicated reporter plasmids in
SK and SK-TRβ cells cotransfected with siControl or
siNCoR in the presence of an expression vector for
NCoR (CMV-NCoR) or the empty vector (CMV). Lu-
ciferase activity (means ± SD) was determined in cells
treated with and without T3.
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metastatic gene transcription. In addition, NCoR overexpression
inhibited the stimulatory effect of siNCoR, again eliminating off-
target effects of the siRNA.
NCoR Inhibits Invasion and Metastasis. The identification of NCoR
as an important regulator of genes that are well documented as
playing a role in cancer progression suggested that this protein
might play a role in invasion, tumor growth, or metastasis. There-
fore we first investigated the role of NCoR in cell invasion in
Transwell Matrigel assays. NCoR depletion increased the invasive
capacity of SK, HepG2, and MDA cells and to a significant extent
reversed the reduced invasion of TRβ in both the absence and
presence of T3 (Fig. 3A and Fig. S3A). NCoR overexpression re-
duced invasion and antagonized stimulation by siNCoR in SK and
SK-TRβ cells (Fig. 3B). Therefore, the corepressor has a functional
role as an inhibitor of cellular invasion and plays a critical function
in mediating the repressive effect of TRβ. In contrast, depletion of
SMRT had no effect (Fig. S3B), indicating that SMRT is not a
regulator of invasion in these cells.
To analyze whether NCoR also could play a role in cell in-
vasion in vivo, SK and SK-TRβ cells transfected with control or
NCoR siRNAs were injected into the tail vein of nude mice.
Fig. 3. NCoR inhibits invasion, extravasation, and
metastatic growth. (A) Invasion assays in Matrigel of
SK and SK-TRβ cells that had been transfected with
siControl or siNCoR 72 h previously. Invasion lasted
for the last 16 h in the presence and absence of T3. The
number of cells per field passing the filter (mean ± SD)
was scored under the microscope and is shown on the
y axis. (B) Similar assays in cells transfected as indicated
with siNCoR, CMV-NCoR, or the corresponding con-
trols. (C) Extravasation assays in nude mice of cells
transfected with siControl or siNCoR. Data (mean ± SE)
are expressed as the percentage of the inoculated cells
found in the lung. (D) Extravasation of SK-TRβ cells
transfected with siNCoR or CMV-NCoR or with the
corresponding controls alone and in combination was
analyzed by determination of human Alu sequences in
the lungs. (E, Left) Metastatic lesions (surrounded by
circles) in lungs from nude mice that had been in-
oculated 30 d previously via the tail vein with cells
transfected with siControl or siNCoR. (Right) The per-
cent of animals with metastases and number of le-
sions per lung (mean ± SE). (F) Relative transcript
levels of NCoR and the indicated prometastatic genes
(mean ± SD) in metastases excised from the lungs by
laser-capture microdissection.
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NCoR depletion increased the amount of SK cells present in the
lungs very significantly and increased the extravasation of TRβ-
expressing cells to levels similar to those found in the parental
cells (Fig. 3C). The augmented extravasation of TRβ-expressing
cells transfected with siNCoR was again reversed by NCoR ex-
pression (Fig. 3D), demonstrating the specificity of the effects of
the corepressor on the invasive properties of the cancer cells in
vivo. Because NCoR limits cancer cell extravasation, it should
act as an inhibitor of metastatic growth. Thus we next analyzed
the effect of NCoR depletion in the formation of lung metastasis
by SK and SK-TRβ cells 30 d after i.v. injection. The incidence of
metastasis was increased in mice inoculated with SK cells trans-
fected with siNCoR. Furthermore, SK-TRβ cells showed a reduced
metastatic capacity (24), but this capacity increased significantly in
the absence of NCoR. Both the incidence of lung metastasis and
the number of metastatic lesions were enhanced significantly in the
absence of the corepressor (Fig. 3E). Therefore, NCoR suppresses
the metastatic potential in vivo. We next isolated the metastatic
lesions by laser-capture microdissection to analyze the expression
of NCoR and prometastatic genes. Strikingly, even at 30 d post-
injection NCoR transcripts were significantly reduced in the me-
tastases formed by cells originally transfected with siNCoR.
Reduction was particularly apparent in metastases from SK-TRβ
cells that expressed higher levels of the corepressor. Furthermore,
prometastatic genes were derepressed in the metastasis after
NCoR depletion (Fig. 3F). The finding that NCoR knockdown
with siRNA lasted for a very long time suggests the existence of a
positive autoregulatory loop that maintains NCoR gene expression.
Tumors Formed by NCoR-Depleted Cells Are Bigger and More Invasive.
To examine the tumor-suppressive effect of NCoR in vivo further,
we conducted xenograft studies with SK and SK-TRβ cells trans-
fected with siControl or siNCoR. NCoR depletion increased tumor
volume in both parental and TRβ-expressing cells. Differences
were observed as early as 2 wk after inoculation and were main-
tained during the whole experimental period (6 wk) (Fig. 4A). In
explants from tumors obtained at 2 wk, NCoR depletion was
maintained in both SK and SK-TRβ cells. Furthermore, there was a
significant positive correlation between the levels of NCoR and
TRβ mRNAs and an inverse relationship between expression of the
corepressor and the mRNA levels of several prometastatic genes,
again indicating the crucial role of NCoR in prometastatic gene
expression (Fig. S4).
The increased size of tumors formed by cells transfected with
siNCoR correlated with a higher proliferation rate (Fig. 4B).
Tumors that originated from parental SK cells were more pro-
liferative than those formed by SK-TRβ cells, and NCoR de-
pletion markedly increased the number of Ki67+ cells. Even 6 wk
after inoculation, strongly reduced NCoR mRNA levels were ob-
served in the tumors formed by SK-TRβ cells originally trans-
fected with siNCoR, and transcript levels of prometastatic genes
were still significantly higher than in tumors that originated from
cells transfected with the control siRNA (Fig. 4C). NCoR de-
pletion also enhanced the invasive capacity of SK-TRβ tumors
(Fig. 4D). Tumors formed by SK-TRβ cells were very compact and
were surrounded by a pseudocapsule, which was lost in NCoR-
deficient tumors that were highly infiltrative. Furthermore, the
percentage of tumors invading bone and muscle was reduced by
TRβ, and this protector effect was lost upon NCoR depletion (Fig.
4D). NCoR knockdown also increased the growth rate of tumors
formed by inoculation of MDA and MDA-TRβ cells into nude
mice (Fig. S5A), and significantly reduced NCoR transcripts also
were found in the breast tumors formed by the cells that had been
transfected with siNCoR 33 d previously (Fig. S5B). In addition,
the noninvasive TRβ-expressing breast tumors became highly in-
filtrative in the absence of the corepressor (Fig. S5B). Therefore,
NCoR acts not only as a suppressor of tumor growth but also as an
inhibitor of tumor invasion in vivo.
NCoR and TRβ Expression Are Reduced in Human HCC and Breast Tumors.
To support the role of NCoR in human cancer further, we collected
human HCC and breast tumors samples. The expression of NCoR
was analyzed by immunohistochemistry in the HCC, in the sur-
rounding cirrhotic tissue, and in normal liver samples (Fig. 5A). In
the normal tissue most nuclei were positive for NCoR, but this
number was reduced in the cirrhotic liver and was markedly inhibi-
ted in the tumors, where less than 10% of the nuclei had detectable
NCoR. These findings were confirmed by immunohistochemistry in
other NCoR-specific antibodies (Fig. S6) and by mRNA analysis.
The results revealed a significant decrease in NCoR mRNA in tu-
mors compared with normal liver, whereas no differences in SMRT
mRNA levels were found. TRβ transcripts also were reduced in the
HCCs, and Dio1, a bona fide TR target gene in liver cells (23),
showed a similar reduction (Fig. 5B). Statistical analysis found a
significant positive correlation (P < 0.001) when TRβ mRNA was
plotted against NCoR or Dio1 mRNAs (Fig. 5C). Strongly reduced
levels of NCoR and TRβ transcripts, without changes in SMRT, also
were found in RNA samples from the more aggressive ER− breast
tumors as compared with ER+ tumors. Again there was a strong
correlation between NCoR and TRβ transcripts (P < 0.001) that
occurred independently of ER status (Fig. 5D). Taken together these
data are consistent with a tumor-suppressive role for the corepressor
in HCC and breast cancer and support the notion that NCoR is a
downstream effector of TRβ in these tumors.
Epigenetic Changes Responsible for Stable NCoR Depletion. Using
cultured cells, we next investigated the mechanism by which tran-
sient NCoR knockdown could lead to long-term deficiency. As
shown in Fig. 6A, 17 d after siNCoR transfection, when several cell
doublings had already occurred, NCoRmRNA was still depleted in
SK and SK-TRβ cells. Furthermore, derepression of ID1 and
COX2 mRNAs was also maintained. In fact, in SK-TRβ cells the
degree of change was similar at 3, 10, and 17 d after siRNA
transfection (Fig. 6B), and at these time points NCoR protein
levels were reduced also (Fig. 6C). NCoR autoregulation is not an
exclusive characteristic of SK cells, because NCoR mRNA levels
also were depleted in MDA andMDA-TRβ cells 17 d after siNCoR
transfection (Fig. 6D).
The long-term NCoR silencing obtained with the siRNA sug-
gested the existence of an epigenetic mechanism that could main-
tain NCoR repression through cell generations. The most typical
inheritable mechanism that could explain these results would
be silencing of the NCoR gene by DNA methylation. Analysis of
the NCoR gene revealed the presence of a regulatory CpG island
spanning −687 to +1557 with respect to the first exon, with the
ATG located in the second exon (Fig. S7A). However, bisulfite
analysis of this fragment showed that the island was unmethylated
to a large extent and that the same nucleotides were modified in SK
and SK-TRβ cells 17 d after transfection with siControl or siNCoR
(Fig. S7B). These results were confirmed by pyrosequencing (Fig.
S7C), thus suggesting that increased methylation of this region was
not responsible for the long-lasting repression of the NCoR gene
upon siRNA transfection.
We then investigated whether recruitment of repressor pro-
teins or increased repressive histone markers could be related to
stable NCoR gene silencing in NCoR-depleted cells. Indeed,
recruitment of SMRT to the +814/+1056 regulatory region of
the NCoR gene increased strongly 24 d after transfection with
siNCoR in SK and SK-TRβ cells (Fig. 7A). Because SMRT also
silences gene expression by HDAC3 recruitment (34), there was a
strong increase in HDAC3 association with the NCoR promoter
(Fig. 7A). These changes occurred without alterations in the ex-
pression of HDAC3 SMRT (Fig. 7B). To test the functional sig-
nificance of this pathway, we next analyzed the effect of SMRT
knockdown in cells previously transfected with siNCoR. NCoR
depletion did not alter SMRT mRNA levels, but the low levels of
NCoR mRNA in cells transfected with siNCoR increased very
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significantly upon SMRT depletion, demonstrating the key role
of SMRT in long-term silencing of the NCoR gene (Fig. 7C).
Moreover, the enhanced expression of the NCoR target gene
COX2 observed in NCoR-depleted cells was reversed, in parallel
with the increased NCoR expression, when SMRT was depleted
also (Fig. 7C). The importance of histone acetylation in the
positive autoregulatory mechanism that maintains NCoR ex-
pression was demonstrated further by the finding that the
HDAC inhibitor trichostatin A (TSA) was a very strong inducer
of NCoR mRNA and protein expression only in cells trans-
fected with siNCoR (Fig. 7 D and E). This effect again was
specific, because it was not observed when SMRT mRNA levels
were determined (Fig. 7D).
Other posttranslational histone modifications such as meth-
ylation of H3K9 have a crucial influence on chromatin structure
and transcriptional repression. H3K9 trimethylation enables bind-
ing of the heterochromatin protein 1 (HP1), which facilitates local
heterochromatinization (35). Furthermore, H3K27 methylation,
another repressive marker, can synergize with HDAC complexes
and H3K9 methylation to silence chromatin (36). Interestingly, we
found that NCoR depletion induced a global cellular increase in the
levels of H3K9me3 and that H3K27me3 levels also were induced,
whereas the total levels of H3 were unaltered in the absence of the
corepressor (Fig. 7F). ChIP assays also showed a strong increase in
the abundance of H3K9me3 and H3K27me3 at the NCoR pro-
moter associated with NCoR knockdown, and under these condi-
tions HP1γ was recruited also (Fig. 7G), thus creating a stably
silenced chromatin state. Examination of the NCoR sequences used
in the ChIP assays showed the existence of three putative SP1-
binding motifs (Fig. 7H). One of the mechanisms by which silencing
was sustained could involve the inhibition of recruitment of key
transcription factors in this repressive chromatin structure. In
agreement with this hypothesis, SP1 bound the NCoR promoter in
cells transfected with siControl, but it was excluded in NCoR-de-
pleted cells (Fig. 7I). Therefore, transcriptional repression of the
NCoR gene in cells transfected with siNCoR appears to be asso-
ciated with heterochromatinization and SP1 removal from the
promoter. This action was specific for the NCoR gene, because
HDAC3 recruitment to the ID1 promoter did not increase in cells
depleted of NCoR and was even clearly reduced in SK-TRβ cells,
as expected for an NCoR target gene. The same results were
obtained with H3K9me3 levels, which were reduced in the cells
transfected with siNCoR despite the higher total levels of this
histone modification (Fig. S8A). In addition, SP1 did not bind to
the ID1 promoter, but its association to the p21 promoter, a well-
known target gene of this transcription factor, was not affected by
NCoR knockdown (Fig. S8B).
To clarify why TSA invokes a strong response in NCoR ex-
pression when other repressive epigenetic marks are also altered,
we tested the possibility that the HDAC inhibitor also could
influence H3K9me3 abundance at the NCoR regulatory region.
ChIP assays showed the expected increase in H3K9 methylation
after NCoR silencing, but this increase was totally inhibited
in TSA-treated cells, coinciding with NCoR derepression. As
expected, heterochromatinization was reversed under these
conditions because SP1 was able to associate with the NCoR
gene (Fig. 7J).
Fig. 4. NCoR inhibits tumor growth and invasion.
(A) Volume of the tumors (mean ± SE) after in-
oculation of cells transfected with siControl or siNCoR
into nude mice. (B) Immunohistochemistry of Ki67 and
the percentage of Ki67+ cells (mean ± SE) in tumors
excised 6 wk after inoculation. (C) Relative transcript
levels of TRβ, NCoR, and the indicated prometastatic
genes (mean ± SE) in the tumors. (D, Left) Represen-
tative Masson´s trichrome staining of tumors, showing
that tumors formed by cells transfected with siNCoR
were more invasive. (Right) The percentage of tumors
that infiltrated bone and muscle.
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Discussion
This work shows the important tumor-suppressive role of the
corepressor NCoR. NCoR inhibits the invasive ability of malig-
nant cells, and knockdown of the corepressor enhances their
ability to grow as invasive tumors, to pass into the circulation,
and to form metastases, agreeing with the circumstantial evi-
dence of reduced NCoR expression in human tumors, in some
cases associated with truncating mutations and homozygous de-
letions of the NCoR gene (19, 21, 22), providing an explanation
for these findings and defining NCoR as a potential target for
cancer therapy.
Increasing evidence indicates that epigenetic alterations in-
volving an altered pattern of histone modifications lead to the
misregulation of gene expression and can contribute to cancer
development (37, 38). Our results show that the tumor-sup-
pressive effects of NCoR are linked to the silencing of genes
involved in metastatic spreading, whose expression has been
associated with poor prognosis in cancer patients (39–44).
NCoR, together with HDAC3, the main enzyme responsible for
the repressive activity of NCoR (45), binds to the promoters of
several prometastatic genes, thereby inhibiting histone acetylation
and repressing their transcription.
An unexpected observation was that transient NCoR silencing
with siRNA led to very long-lasting inhibition of NCoR expres-
sion. This inhibition was observed both in cultured cells and in
the tumors and metastatic lesions and was accompanied by de-
repression of prometastatic genes. Similar to these results, a
single episode of RNAi in Caenorhabditis elegans can induce
Fig. 5. NCoR and TRβ expression in human HCC and
breast cancer tumors. (A, Left) NCoR immunohisto-
chemistry of normal liver, the surrounding cirrhotic
tissue, and HCC NCoR-positive cell nuclei are indicated
by arrows. (Right) The percent of NCoR-positive cells
in the different groups (mean ± SD). (B) Whisker plot
of NCoR, SMRT, TRβ, and Dio1 mRNAs (mean ± SD) in
normal liver and HCC. (C) TRβ mRNA was plotted
against the corresponding NCoR or Dio1 transcripts in
each sample. The P value and linear regression co-
efficient obtained are shown. (D) NCoR, SMRT, and
TRβ mRNAs (mean ± SD) in ER+ (n = 18) and ER− (n =
18) breast tumors. Correlation between NCoR and TRβ
in all tumors as well as independently in ER+ and ER−
tumors is illustrated also.
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inheritable reduced transcription of some genes, which can be
relieved in the presence of TSA (46). Furthermore, some cases
of transgenerational epigenetic inheritance seem to involve inherited
histone methylation patterns (38), and in the nematode long-term
silencing is associated with increased H3K9me3 levels that can be
passed through generations without being lost (18).
Stable NCoR silencing after siRNA occurs via a transcrip-
tional mechanism dependent on changes in chromatin structure.
Despite the presence of a regulatory CpG island within the
NCoR gene, DNA methylation of this region was not involved in
silencing, suggesting that this is not the main mechanism re-
sponsible for NCoR autoregulation. Next, we investigated histone
methylation and found that increased abundance of H3K9me3,
one of the best markers of heterochromatin, and to a lesser extent
of H3K27me3, another repressive marker, were linked to repres-
sion. Remarkably, siRNA-mediated suppression of NCoR in-
creased the global levels of H3K9me3, suggesting that chromatin
structure is globally altered in the absence of the corepressor.
However, we did not find an increase in H3K9me3 association
with other genes. It presently is unclear how the gene-target spec-
ificity is achieved, but it could involve the assembly of different sets
of cofactors and histone-modifying enzymes (1). H3K9 methylation
facilitates the recruitment of HP1 (47, 48), allowing local hetero-
chromatinization (49), and accordingly HP1γ also was recruited to
the silenced NCoR gene. In addition to the increased abundance of
transcriptional repressive methylation markers, siRNA depletion of
NCoR strongly increased HDAC3 association with the NCoR gene.
This paradoxical recruitment in the absence of NCoR was caused
by SMRT recruitment. The existence of cross-talk between post-
translational histone modifications is well known (37), and we found
that inhibiting HDAC activity with TSA also inhibits H3K9me3
abundance at the NCoR gene. Thus, both histone deacetylation and
methylation appear to play important roles in the establishment of a
local repressive state that leads to long-lasting inhibition of NCoR
gene transcription, presumably by providing a heterochromatic en-
vironment that could prevent sequence-specific transcription factor
binding. Indeed, under these conditions SP1 could not bind to the
promoter, in agreement with findings indicating that occlusion
of SP1 binding is associated with increased H3K9me3 (50). In-
terestingly, NCoR depletion could represent an important mech-
anism for tumor progression when noNCoRmutations are present.
A cellular change resulting in a reduction in NCoR levels at a given
point in time could be propagated through many cell generations,
allowing the cancer cell to proliferate and to become invasive.
Our results show that NCoR levels are increased in cancer cell
lines, as well as in nontumoral hepatocytes, after TRβ expression.
Surprisingly, this increase occurred in a ligand-independent man-
ner. It is possible that the unliganded receptor could have
constitutive effects on NCoR expression when expressed at
high concentrations or that residual amounts of thyroid hormones
in the serum could be sufficient for maximal stimulation under
these conditions. NCoR induction appears to play a crucial role in
the antitumorigenic and antimetastatic actions of the receptor
(24), because these actions were reversed almost completely upon
NCoR silencing. We also have shown that, in contrast with the
native receptor, TRβ mutants unable to bind the corepressor can-
not antagonize Ras-mediated transformation and tumorigenesis
(26), reinforcing the idea that NCoR is an essential mediator of the
tumor-suppressive actions of TRβ. TRβ-mediated up-regulation of
NCoR could extend the scope of genes that are influenced by the
receptor, because the corepressor has been shown to repress tran-
scription through other nuclear receptors and numerous transcrip-
tion factors with a role in cancer progression (1, 12). Therefore,
repression of prometastatic gene expression could be a conse-
quence of NCoR interaction with this receptor or, more likely, with
other transcription factors that associate with their promoters. The
findings that the effects of TRβ are largely ligand independent and
that NCoR binds to the promoters of prometastatic genes in pa-
rental SK cells that express very low levels of TR support the hy-
pothesis that NCoR could be recruited to these promoters by other
DNA-binding proteins. The increased levels of NCoR would be
sufficient to account for the T3-independent action of TRβ in
prometastatic gene expression. This action would be particu-
larly important for transcription factors preferentially inter-
acting with NCoR rather than SMRT, because TRβ did not
significantly regulate SMRT. Furthermore, SMRT depletion
affected neither metastatic gene expression nor the invasive
capacity of SK or MDA cancer cells, suggesting the specific role
of NCoR in these processes.
Our data confirm that NCoR mRNA levels are reduced in
human HCC, in agreement with the finding that Hdac3 deletion
in mice causes the appearance of these tumors (22). Further-
more, NCoR expression was decreased in the cirrhotic peritu-
moral tissue, which is considered to be precancerous, further
supporting a tumor-suppressive role for NCoR in human HCC.
On the other hand, hypothyroidism has been considered to be a
risk factor for the development of HCC in humans (51, 52), and
Fig. 6. NCoR depletion with siRNA leads to long-term reduction of NCoR
gene expression. (A) NCOR, COX2, and ID1 transcripts (means ± SD) in SK and
SK-TRβ cells that had been transfected with siControl or siNCoR 17 d pre-
viously. (B) The same mRNAs quantitated at 3, 10, and 17 d posttransfection
in SK-TRβ cells. Data are means ± SD. (C) Western blot analysis of NCoR
expression with Santa Cruz (SC) and Bethyl antibodies 17 d after SK-TRβ cells
were transfected with siControl or siNCoR. (D) NCoR transcripts (means ± SD)
in MDA and MDA-TRβ cells 17 d after transfection with siControl or siNCoR.
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TRβ down-regulation has been reported recently to be an early
event in human and rat HCC development (29). Interestingly, we
found that TRβ transcripts not only were significantly reduced in
the tumors compared with normal tissues but also correlated
positively with the levels of the corepressor. A strong correlation
between TRβ and NCoR expression also was found in human
breast tumors and, interestingly, both genes were markedly
down-regulated in ER− tumors as compared with ER+ tumors
that have a better prognosis. Thus, our results support the pos-
sibility that the receptor is an upstream stimulator of NCoR gene
expression and suggest that NCoR and TRβ could be considered
potential biomarkers for some types of human cancers.
Although the mechanisms underlying the role of chromatin reg-
ulation in oncogenesis are complex and remain to be defined in a
cellular context-dependent manner, our data hold the potential of
defining the epigenetic signatures associated with NCoR expression
in tumors for potential use as diagnostic or prognostic markers.
Elucidating the link between epigenetic mechanisms connecting
NCoR loss and tumor progression should prompt the development
of more efficient therapeutic strategies as well as facilitate a better
understanding of tumor biology.
Materials and Methods
Extended materials and methods are provided in SI Materials and Methods.
Animal and human studies were approved by the Ethics Committees of the
Ramón and Cajal Hospital and the Consejo Superior de Investigaciones
Científicas. Informed consent was obtained for the study. NCoR and SMRT
were knocked down in parental and TRβ-expressing cells with specific siRNA
SMART pools from Dharmacon. Experimental procedures for transfections,
luciferase reporter assays, Western blot, mRNA determination by real-time
PCR, and ChIP assays have been published previously and are described to-
gether with the antibodies and primers used in SI Materials and Methods.
Clinical and pathological characteristics of HCC and breast cancer samples
are given in Tables S1 and S2. Invasion assays in vitro in Transwell plates
containing Matrigel and extravasation assays to the lung in vivo were per-
formed as previously described (24, 25). Metastasis formation in the lungs was
determined 30 d after inoculation of tumor cells into the tail vein of nude
mice, and tumor formation was followed for 6 wk after inoculation into the
flanks or the mammary pad. Lung areas affected by metastasis were dissected
Fig. 7. Heterochromatinization of the NCoR gene
after NCoR depletion with siRNA. (A) ChIP assays of
SMRT and HDAC3 with the +814/+1056 region of the
NCoR gene with respect to the first exon in SK and
SK-TRβ cells that had been transfected with siControl
or siNCoR 24 d previously. (B) Western blot analysis
of HDAC3, SMRT (with Upstate antibodies), SP1, and
ERK in SK and SK-TRβ cells that had been transfected
with siControl or siNCoR 3 and 12 d previously.
(C) SMRT, NCoR, and COX2 transcripts (means ± SD)
in cells transfected with siControl or siNCoR for 17 d
and with siSMRT for the final 3 d. (D) NCoR and
SMRT mRNA levels in SK-TRβ cells that had been
transfected with the control or NCoR siRNAs 17 d
previously and treated with 300 nM TSA for the last
24 h. (E) Western blot of NCoR and SMRT with the
indicated antibodies in SK-TRβ cells that had been
transfected with siControl or siNCoR 17 d previously
and treated with TSA during the last 24 h. (F) Western
blot of NCoR, ERK, SMRT, H3K9me3, H3K27me3, and
total H3 in the groups shown in B. (G) Recruitment of
H3K9me3, H3K27me3, and HP1γ to the +814/+1056
region of the NCoR gene. ChIP assays were performed
in SK and SK-TRβ cells that had been transfected with
siControl or siNCoR 24 d previously. (H) Sequence of
the +814/+1056 fragment of the NCoR gene showing
putative binding sites for SP1 in red. (I) SP1 recruitment
to theNCoR gene in the conditions shown inG. (J) ChIP
assays with IgG, H3K9me3, and SP1 antibodies in cells
that had been transfected with siControl or siNCoR for
15 d and with TSA during the last 24 h.
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by laser-capture microdissection, and RNA was extracted. Histology and im-
munohistochemistry were performed by standard procedures. Significance of
ANOVA posttest or the Student t test among the experimental groups in-
dicated in the figures is shown as *P < 0.05, **P < 0.01, and ***P < 0.001.
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